Esophageal cancer
Conditions
Sponsors
The Second Affiliated Hospital of Xi'an Jiaotong University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18 to 75 years; 2. Pathology confirmed as esophageal squamous cell carcinoma and Clinical stage is II-III; 3. Initial treatment, No surgery history; 4. ECOG 0~2; 5. Expected survival >=3 months; 6. All the patients should have target lesions that are measurable and evaluable; 7. Should be able to consume liquid diet, no esophageal perforation symptoms, no distant metastases; 8. The main organ function is normal, which meets the following criteria: (1) The standard of blood test should be met (14 days without blood transfusion and blood products, no G-CSF and other hematopoietic stimulation factor correction): Hb>=100g/L;ANC>=1.5x10^9/L;PLT>=100x10^9/L; (2) Biochemical inspection shall meet the following criteria: TBIL 50 ml/min (the Cockcroft Gault formula); (3) Pulmonary function FEV1 >=1 L or >50% of corresponding value of normal people; 9. Female during the reproductive period should be ensured contraception during the study period; 10. Participants voluntarily joined the study, signed informed consent, and had good compliance and follow-up.
Exclusion criteria
Exclusion criteria: 1. Patients who do not meet the pathological type of the inclusion criteria and the primary site; 2. Allergic to recombinant endostar, carboplatin, paclitaxel, and contrast agents; 3. Have a distant metastasis; 4. The primary focal tumors or lymph node already had a surgical treatment (except for biopsy), chemoradiotherapy or targeted therapy; 5. Patient who suffered from other malignant tumor; 6. Subject with severe pulmonary and cardiopathic disease history; 7. Pregnant woman or Lactating Women and Women in productive age who refuse take contraception in observation period; 8. Subject with a Personality or psychiatric diseases, people with no legal capacity or people with limited capacity for civil conduct; 9. Received other medicine trials in past 4 weeks; 10. Refuse or incapable to sign the informed consent form of participating this trial; 11. The researchers judged other conditions that could affect clinical research and the results of the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Objective response rate;Progression-free survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| Disease control rate;Overall survival;drug safety;Blood routine examination; | — |
Countries
China
Contacts
Public ContactHongbing Ma
Outcome results
None listed